Biotech Breakthrough: Zivo Bioscience Unveils Revolutionary Non-Antibiotic Treatment for Poultry Disease
Zivo Bioscience, Inc., a pioneering biotech/agtech R&D company, has just announced a game-changing development in the battle against coccidiosis in broiler chickens. In a recent 42-day coccidiosis challenge study, the company's innovative immune-modulating treatment has shown remarkable efficacy, setting a new standard in poultry health management. This breakthrough product, designed for inclusion in poultry feed, enhances the birds' immune response, enabling them to effectively combat the debilitating effects of coccidiosis without relying on antibiotics.
Building on the success of a prior 28-day study, this extended 42-day trial was conducted to mirror the real-world conditions of the broiler production industry. The impressive results, which were blind-tested by an independent study contractor, reaffirm the positive effects of ZIVO's non-antibiotic alternative in maintaining broiler health. Notably, the performance of ZIVO’s product candidate proved comparable to that of a leading anticoccidial product in the market, which contains an antibiotic and an anti-coccidial chemical.
John Payne, Chairman and CEO of ZIVO Bioscience, expressed his enthusiasm about the study's results, highlighting the product's potential to transform the industry. "We are thrilled with the outcomes of our studies, which demonstrate that our coccidiosis treatment is not only effective in real-world conditions but also avoids the undesirable attributes associated with antibiotics and chemicals," said Payne.
The success of this novel treatment opens up new horizons for poultry health management. It showcases the potential of non-antibiotic solutions in addressing significant health challenges in the poultry industry, such as coccidiosis - a protozoal disease that causes severe gastrointestinal issues, decreased performance, and increased mortality in poultry. The economic impact of this disease is substantial, with annual costs estimated between $10 billion to $17 billion, making this breakthrough all the more significant.
With these promising results in hand, ZIVO is now set to partner with a global animal health company to bring this revolutionary product to the market. The goal is to complete licensing through the USDA and commercialize the product, offering a cost-effective, efficient, and safer alternative to traditional antibiotic and antimicrobial interventions.
This announcement from ZIVO Bioscience marks a significant leap forward in addressing the urgent need for new, effective treatments for coccidiosis. It represents not only a win for poultry health but also a step toward a more sustainable and responsible approach to animal agriculture.
